ARG65607
anti-CD261 / TRAIL R1 antibody [DR-4-02] (low endotoxin)
anti-CD261 / TRAIL R1 antibody [DR-4-02] (low endotoxin) for Flow cytometry,Functional study,ICC/IF,Immunoprecipitation and Human
Cell Biology and Cellular Response antibody; Cell Death antibody; Immune System antibody
Overview
| Product Description | Low endotoxin Mouse Monoclonal antibody [DR-4-02] recognizes CD261 / TRAIL R1 |
|---|---|
| Tested Reactivity | Hu |
| Tested Application | FACS, FuncSt, ICC/IF, IP |
| Specificity | This antibody recognizes TRAIL-R1 (DR4), a human death receptor 4 (468 amino acids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour-derived cell lines. |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | DR-4-02 |
| Isotype | IgG1 |
| Target Name | CD261 / TRAIL R1 |
| Antigen Species | Human |
| Immunogen | Fusion protein containing Human TRAIL-R1 (extracellular part) and Human IgG1 heavy chain (constant part). |
| Conjugation | Un-conjugated |
| Alternate Names | TNF-related apoptosis-inducing ligand receptor 1; CD antigen CD261; TRAILR-1; DR4; Tumor necrosis factor receptor superfamily member 10A; CD261; Death receptor 4; APO2; TRAIL receptor 1; TRAIL-R1; TRAILR1 |
Application Instructions
| Application Suggestion |
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Application Note | Functional Application: Soluble antibody DR-4-02 blocks apoptosis triggered by a ligand (TRAIL). Plastic-immobilized (cross-linked) DR-4-02 antibody induces apoptosis in sensitive cells. Recommended dilution of antibody: 2-3 μg/ml in cultivation medium Final concentration of TRAIL: 20-200 ng/ml Application note: It is recommended to add the antibody 15 min before addition of TRAIL. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. |
Properties
| Form | Liquid |
|---|---|
| Purification | Purification with Protein A. |
| Purification Note | 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein. |
| Purity | > 95% (by SDS-PAGE) |
| Buffer | PBS (pH 7.4) |
| Concentration | 1 mg/ml |
| Storage Instruction | For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Database Links |
Swiss-port # O00220 Human Tumor necrosis factor receptor superfamily member 10A |
|---|---|
| Gene Symbol | TNFRSF10A |
| Gene Full Name | tumor necrosis factor receptor superfamily, member 10a |
| Background | The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. [provided by RefSeq, Jul 2008] |
| Function | Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. [UniProt] |
| Research Area | Cell Biology and Cellular Response antibody; Cell Death antibody; Immune System antibody |
| Calculated MW | 50 kDa |
Images (2) Click the Picture to Zoom In
-
ARG65607 anti-CD261 / TRAIL R1 antibody [DR-4-02] (low endotoxin) FACS image
Flow Cytometry: Two hematopoietic cell lines stained with ARG65607 anti-CD261 / TRAIL R1 antibody [DR-4-02] (low endotoxin) followed by incubation with PE-labelled secondary antibody.
Red: secondary antibody (no primary antibody).
Black: anti-TRAIL-R1 comparative antibody.
Blue and Green: Primary antibody in duplicate staining. -
ARG65607 anti-CD261 / TRAIL R1 antibody [DR-4-02] (low endotoxin) ICC/IF image
Immunofluorescence: HeLa Human cervix carcinoma cell line transfected with DR4 expression plasmid and stained with ARG65607 anti-CD261 / TRAIL R1 antibody [DR-4-02] (low endotoxin).
Clone References
Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.
Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.
FACS / Human
Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
ICC/IF / Human
Scatter factor protects tumor cells against apoptosis caused by TRAIL.
IP /
Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis.
